Botensilimab and balstilimab combination therapy is approved in France for ovarian cancers and soft tissue sarcomas under the AAC framework. The therapy, initially for microsatellite-stable metastatic ...
CRC leads BOT+BAL clinical development: 42% two-year overall survival and ~21-month median overall survival in heavily pretreated microsatellite stable (MSS) metastatic CRC (mCRC) patients BATTMAN ...
Agenus (AGEN) announced new data from its botensilimab, BOT, a multifunctional, Fc-enhanced CTLA-4 antibody and balstilimab, BAL, a PD-1 inhibitor, combination demonstrating durable survival across ...
Prognosis of patients with liver single-organ metastases: Updated survival results of BBCAPX-II. The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical ...
First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease features In the overall BOT+BAL treated ...
Noetik’s TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survival In a ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc (AGEN). (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results